NFN8 Group, Inc., an Austin, Texas company that sold investors interests in cryptocurrency-mining equipment and “hosting” arrangements, filed for Chapter...
Read MoreLipella Pharmaceuticals Bankruptcy — Spartan Capital Securities and H.C. Wainwright Investors May Have Claims
Lipella Pharmaceuticals Inc. (formerly Nasdaq: LIPO), a Pittsburgh clinical-stage drug developer, filed a voluntary Chapter 11 petition in the United States Bankruptcy Court for the Western District of Pennsylvania on March 30, 2026 (Case No. 26-20879). In the fifteen months before that filing, the company raised millions of dollars from investors in a series of private placements — and paid more than $1.7 million in commissions to a single broker-dealer to do it.
Carlson Law is evaluating potential claims for investors who purchased Lipella stock, preferred stock, or warrants through Spartan Capital Securities, H.C. Wainwright & Co., or any other brokerage firm.
A timeline of Lipella’s broker-sold offerings
SEC filings show Lipella relied on brokers at nearly every stage of its life as a public company:
| Form D/A — May 17, 2021 | $3.6M private placement, $3.12M sold; sales commissions $40,500 to Spartan Capital Securities, LLC |
| IPO — 424B4 December 21, 2022 | 1,217,391 shares at $5.75 ($7.0M); underwriting discounts $629,999.84 (see prospectus for underwriter) |
| Form D — November 7, 2023 | $2,000,000 placement; sales commissions $150,000 to H.C. Wainwright & Co., LLC |
| 424B5 — August 1, 2024 | Registered direct offering; H.C. Wainwright engaged as exclusive placement agent |
| Form D — January 7, 2025 | $6,000,000 offering, $2,597,500 sold; sales commissions $441,575 to Spartan Capital Securities (rep Eric P. Meyer) |
| Form D — April 1, 2025 | Sales commissions of $1,104,000 reported to Spartan Capital Securities (rep Eric P. Meyer) |
| 424B5 — April 4, 2025 | At-the-market program of up to $2.64M with H.C. Wainwright as sales agent |
| Resale prospectuses — January and April 2025 | Registration of common stock underlying Series B and C preferred and placement-agent warrants |
The firms
| Firm / representative | Role per SEC filing |
| Spartan Capital Securities, LLC | Placement agent on 2021, January 2025 and April 2025 private placements; $1,586,075 in reported commissions |
| Eric P. Meyer (Spartan Capital) | Registered representative identified on the 2025 Form D filings |
| H.C. Wainwright & Co., LLC | Placement agent (2023, 2024) and ATM sales agent (2025) |
Spartan Capital is a retail brokerage with a lengthy public disciplinary record on FINRA BrokerCheck. Its customers are typically individual investors, not institutions. Placing more than $1 million in commissions on a micro-cap biotech’s preferred stock in the spring of 2025 — within a year of the company’s collapse — raises obvious questions about what the firm knew and what it told the people it sold to.
The legal standard
A brokerage firm that recommends a speculative private placement to a retail customer must (1) investigate the issuer before selling (FINRA Regulatory Notice 10-22), (2) have a reasonable basis to believe the investment is suitable for that customer (FINRA Rule 2111), and (3) act in the customer’s best interest, which includes a duty not to place its own compensation ahead of the customer’s welfare (SEC Regulation Best Interest). Micro-cap preferred stock with warrants, sold to fund a company that was burning cash, is among the riskiest products a retail investor can own.
Lipella investors: contact us
If you bought Lipella securities through Spartan Capital, H.C. Wainwright, or another broker, your claim is against the brokerage firm — not just the bankrupt company.
Carlson Law represents investors throughout the United States in claims against financial advisors and investment firms. If you or a loved one have suffered investment losses, please call us at 888-976-6111 or complete our contact form for a free and confidential consultation.
